Abstract
Two years is a long time in the world of RNAi therapeutics. Since Science last covered the topic in 2007, the first Phase 3 human clinical trial of an siRNA drug has been prematurely terminated; new off-target effects have been identified; and the first miRNA-based therapeutic entered clinical trials. Yet much remains the same, especially the biggest challenge: delivery. As researchers struggle to overcome these obstacles, optimism persists undiminished.
Publisher
American Association for the Advancement of Science (AAAS)
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献